Abingworth invests in €33m round for Epigenomics

Following the transaction, Abingworth will become the largest shareholder in the company.

German Epigenomics AG completed the placement of 14.7 million new ordinary bearer shares, which were placed at the subscription price of  €2.25 per new share resulting in gross proceeds of about €33.1 million.

The rights offering started on 15 March and ended on 29 March. ICF Kursmakler AG acted as sole lead manager and sole underwriter.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• Venture